Spondyloarthropathies
News from the FDA/CDC
Upadacitinib earns FDA approval for ankylosing spondylitis
Janus kinase inhibitor offers oral option for patients who have who have had an insufficient response or intolerance with one or more tumor...
Conference Coverage
IBD risk ‘uncertain’ in biologic-treated AxSpA patients
“Enormous uncertainty” surrounds the risk of inflammatory bowel disease associated with biologic treatment in patients with axial...
News from the FDA/CDC
U.S. FDA warns of hidden drug ingredients in certain supplements products
The products are marketed to treat arthritis, muscle pain and other conditions and are sold online and in some retail stores with variations of...
From the Journals
TNF inhibitor treatment models promote personalized care in ankylosing spondylitis
A retrospective cohort study of 10 randomized, controlled trials showed the ability of baseline variables to predict response to tumor necrosis...
From the Journals
Medicare Part D beneficiaries without low-income subsidy less apt to fill prescriptions for pricey drugs
An analysis of more than 17,000 prescriptions written between 2012 and 2018 for Part D beneficiaries revealed that patients receiving subsidies...
From the Journals
Drug survival study looks at what lasts longest in RA, axSpA, PsA, and psoriasis
Survival rates were highest for rituximab in rheumatoid arthritis and golimumab in axial spondyloarthritis in a study of two Danish registries.
Guidelines
Updated perioperative guidance says when to hold antirheumatics
Rheumatologists and orthopedic surgeons revise advice on JAK inhibitors and add new medications.
Commentary
Dietary recommendations for inflammatory rheumatic diseases
France’s first set of dietary recommendations for chronic inflammatory rheumatic diseases are a welcome guide for health care professionals and...
From the Journals
Tofacitinib’s cancer, cardiovascular risks outlined in older rheumatoid arthritis patients
A study estimated that, during 5 years of therapy, for every 113 RA patients treated with 5 mg of tofacitinib twice daily instead of a TNF...
From the Journals
Proactive infliximab monitoring found best for sustaining control of inflammatory diseases
Proactive therapeutic drug monitoring with maintenance infliximab proved more effective in sustaining disease control than did standard care in...
News from the FDA/CDC
Tofacitinib approved for new ankylosing spondylitis indication
The action makes the drug the first Janus kinase (JAK) inhibitor to be approved for ankylosing spondylitis.